Sugi Predict

Sugi Predict / Compounds / SCHEMBL863638

SCHEMBL863638

SCHEMBL863638

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC(=O)C4CCCC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.74
▸ NPC1L1 Q9UHC9 2/20 0.74
▸ LMNA P02545 2/20 0.74
▸ SRD5A1 P18405 6/20 0.55
▸ SRD5A2 P31213 3/20 0.55
▸ FNTA P49354 3/20 0.55
▸ FNTB P49356 3/20 0.55
▸ CDC25A P30304 4/20 0.54
▸ CDC25B P30305 1/20 0.53
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ ABCB1 P08183 1/20 0.51
▸ OSBP P22059 1/20 0.51
▸ RORC P51449 1/20 0.51
▸ OSBP2 Q969R2 1/20 0.51
▸ CYP46A1 Q9Y6A2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29015206 1.00 USP2 (0.74) USP2NPC1L1LMNASRD5A1SRD5A2
SCHEMBL14924215 1.00 USP2 (0.74) USP2NPC1L1LMNASRD5A1SRD5A2
SCHEMBL248175 0.90 LMNA (0.63) USP2NPC1L1LMNASRD5A1SRD5A2
SCHEMBL10584542 0.87 LMNA (0.57) USP2NPC1L1LMNASRD5A1SRD5A2
SCHEMBL26653759 0.87 NPC1L1 (0.60) USP2NPC1L1LMNAFNTAFNTB
SCHEMBL10698627 0.86 LMNA (0.55) USP2NPC1L1LMNA
SCHEMBL29289385 0.86 GPBAR1 (0.69) USP2NPC1L1LMNAFNTAFNTB
SCHEMBL2482340 0.86 USP2 (0.73) USP2NPC1L1LMNASRD5A1SRD5A2
SCHEMBL2482342 0.86 USP2 (0.73) USP2NPC1L1LMNASRD5A1SRD5A2
SCHEMBL248173 0.85 NPC1L1 (0.72) USP2NPC1L1LMNASRD5A1SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11590187-B2 Antimicrobial compositions SHAMAN NATURALS, LLC (US) 2023-02-28 — — US claimed
US-20170176446-A1 Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2017-06-22 — — US claimed
US-9267945-B2 Diagnosis of multiple sclerosis YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2016-02-23 — — US claimed
EP-2389589-B1 METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS BRIGHAM & WOMENS HOSPITAL (US) 2015-08-12 — — EP claimed
US-20140343095-A1 Methods of Diagnosing and Treating Multiple Sclerosis THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2014-11-20 — — US claimed
US-20120077770-A1 Methods of Diagnosing and Treating Multiple Sclerosis THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-03-29 — — US claimed
EP-2389589-A2 METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS Brigham and Women's Hospital, Inc. (US) 2011-11-30 — — EP claimed
WO-2010090859-A2 METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2010-08-12 — — WO claimed
WO-2025242860-A3 PHYTOSTEROL DERIVATIVES, AND COMPOSITIONS COMPRISING THE SAME, FOR USE AS MEDICAMENTS Institut National de la Santé et de la Recherche Médicale (FR) 2026-01-02 — — WO disclosed
WO-2025242860-A2 PHYTOSTEROL DERIVATIVES, AND COMPOSITIONS COMPRISING THE SAME, FOR USE AS MEDICAMENTS Institut National de la Santé et de la Recherche Médicale (FR) 2025-11-27 — — WO disclosed
WO-2025242860-A2 PHYTOSTEROL DERIVATIVES, AND COMPOSITIONS COMPRISING THE SAME, FOR USE AS MEDICAMENTS Institut National de la Santé et de la Recherche Médicale (FR) 2025-11-27 — — WO disclosed
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS INC (US) 2025-10-16 — — US disclosed
CN-119912515-A Method for simultaneously extracting beta-ecdysone and dew grass polysaccharide from dew grass 湖南绿蔓生物科技股份有限公司 2025-05-02 — — CN disclosed
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
WO-2010090859-A3 METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2010-12-09 — — WO disclosed
EP-2219587-A1 STEROL-MODIFIED AMPHIPHILIC LIPIDS The Regents of the University of California (US) 2010-08-25 — — EP disclosed
WO-2010090859-A2 METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2010-08-12 — — WO disclosed
WO-2010090859-A2 METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2010-08-12 — — WO disclosed
WO-2010055510-A2 DIAGNOSIS OF MULTIPLE SCLEROSIS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2010-05-20 — — WO disclosed
WO-2009064696-A1 STEROL-MODIFIED AMPHIPHILIC LIPIDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS APOB, APOL1, LDLR USP2 2046/4885NPC1L1 14/4885LMNA 161/4885
US-11590187-B2 Antimicrobial compositions CNR2, CNR1, FPR3 USP2 3041/4885NPC1L1 69/4885LMNA 3724/4885
US-20170176446-A1 Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer MYC, CCNO, MKI67 USP2 500/4885NPC1L1 1153/4885LMNA 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.